Hyperfine, Inc. develops and commercializes the Swoop® system, an FDA-cleared, AI-powered portable ultra-low-field magnetic resonance brain imaging system. News about HYPR centers on Swoop deployments across hospitals, emergency departments, ICUs, neurology offices, and international markets; regulatory clearances such as CE and UKCA marks; and Optive AI™ software updates tied to brain imaging workflows.
Company updates also cover quarterly results, clinical data and publications in stroke and neuroimaging, distributor and customer activity, financing arrangements, and healthcare-conference participation.
Hyperfine (Nasdaq: HYPR) announced on October 15, 2025 that it has commenced an underwritten public offering of its Class A common stock or, for certain investors, pre-funded warrants to purchase Class A common stock. The company said all securities will be sold by Hyperfine and that underwriters will have a 30-day option to buy up to 15% of the total securities on the same terms. The offering is subject to market and other conditions and may not be completed.
Lake Street Capital Markets is sole book-runner. The securities are offered from an effective Form S-3 shelf registration (filed Nov 9, 2023; declared effective Nov 22, 2023). Final terms will be disclosed in a prospectus supplement filed with the SEC.
Hyperfine (Nasdaq: HYPR) reported preliminary, unaudited Q3 2025 results and business progress following the launch of the next generation Swoop system and Optive AI software. Preliminary Q3 revenue is expected to be ~$3.4M (sequential +27%); preliminary effective average device selling price is ~$360,000 (sequential +36%).
In Q3, 5 of 8 commercial Swoop systems sold (63%) were next generation units. Preliminary cash burn was ~$5.9M (sequential -27%), with preliminary cash and cash equivalents of ~$21.6M as of September 30, 2025. The company began office-setting launches and Optive AI rollout to installed base in US, Canada, Australia, and New Zealand.
Hyperfine (NASDAQ: HYPR) distribution partner UpCare Europe won a UniHA national referencing to supply the Swoop® AI-powered portable MRI system to France’s public hospitals. The framework covers procurement access for more than 1,500 public hospitals and 130 regional hospital groups and is effective November 2, 2025. The agreement allows Swoop® purchases over a three-year period and is the first inclusion of portable brain MRI in the UniHA framework. The release also notes recent CE marking of Hyperfine’s Optive AI software. The arrangement removes the need for individual tenders, streamlining adoption and enabling broader deployment of portable brain imaging across France.
Summary not available.
Hyperfine (NASDAQ: HYPR) has secured CE Mark and UKCA approval for its Optive AI™ software, expanding the global reach of its AI-powered imaging technology. The software enhances the Swoop® portable MRI system's image quality through advanced AI processing at multiple stages, from noise cancellation to post-processing.
The approval follows recent FDA clearance and enables deployment in European and UK markets starting Q4 2025. The software upgrade is compatible with first-generation Swoop® systems without hardware modifications, offering enhanced brain imaging capabilities for various clinical applications including stroke, pediatric care, and neurodegenerative conditions.
Hyperfine (Nasdaq: HYPR), creator of the first FDA-cleared AI-powered portable MR brain imaging system - the Swoop® system - announced its participation in two upcoming investor conferences. The company will present at the H.C. Wainwright Global Investment Conference on September 8, 2025, and the Lake Street Capital Markets Best Ideas Growth Conference on September 11, 2025.
During these events, management will discuss recent milestones including two major technology clearances, the launch of their next-generation Swoop® system with Optive AI™ software, new office business initiatives, hospital growth plans, and clinical evidence updates.
Hyperfine (NASDAQ:HYPR), creator of the Swoop® AI-powered portable MRI system, reported strong Q2 2025 results with revenues of $2.7M, up 26% sequentially. The company sold 8 Swoop® systems in Q2, increasing from 6 units in Q1, while gross margin improved 800 basis points to 49.3%.
Key achievements include FDA clearances for Optive AI™ software and next-gen Swoop® system, successful completion of neurology office pilot program, and enrollment of the 100th patient in the NEURO PMR study. The company's AI technology showed 100% sensitivity in detecting ARIA-E in Alzheimer's patients during Lecanemab therapy trials.
Management maintains 2025 revenue growth guidance of 10-20% over 2024 and expects reduced cash burn of $27-29M for 2025, a 27% improvement from 2024.
Hyperfine (Nasdaq: HYPR) has reached a significant milestone in its NEURO PMR study, enrolling 100 patients within just 16 weeks, ahead of the planned schedule. The study, conducted at DENT Neurologic Institute and Texas Neurology, evaluates the company's next-generation Swoop® system, an FDA-cleared AI-powered portable MRI system for brain imaging in outpatient settings.
The multi-center study compares portable ultra-low-field MRI with conventional high-field MRI in neurology offices, with results expected in early 2026. The company has strategically partnered with NeuroNet Pro, the largest U.S. association of independent neurology practices, to expand commercial adoption. The milestone follows Hyperfine's successful office pilot program, where early adopters implemented Swoop® systems and obtained reimbursement from CMS and private insurers.
Hyperfine (Nasdaq: HYPR) has announced the initiation of the PRIME (Portable Rapid Imaging for Medical Emergencies) study, enrolling its first patients at Yale School of Medicine. The study will evaluate the company's AI-powered Swoop® portable MRI system in emergency department settings.
The PRIME study expands upon the previous ACTION PMR study and will utilize the next-generation Swoop® system with Optive AI™ software, featuring enhanced image quality and sharper anatomical detail. The research aims to assess the technology's effectiveness as a triage tool for various brain-related emergency conditions in a Level 1 emergency department.
Led by Dr. Kevin Sheth and Dr. Adam De Havenon, the study focuses on addressing critical challenges in emergency departments, including patient boarding and limited MRI access. The initiative aligns with Hyperfine's strategy to drive commercial growth by demonstrating how portable MRI can improve clinical workflows and diagnostic access at the point of care.
Hyperfine (Nasdaq: HYPR), known for developing the Swoop® system - the first FDA-cleared AI-powered portable MRI system for brain imaging, has scheduled its Q2 2025 financial results announcement for August 13, 2025.
The company will host a conference call at 1:30 PM PT / 4:30 PM ET on the same day. Investors can access the live audio webcast and recording through Hyperfine's investor relations website. Participants are advised to register at least 15 minutes before the call.